14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of a Pilot Study of the German Hodgkin’s Lymphoma Study Group

Sieber, M.; Bredenfeld, Henning; Josting, Andreas; Reineke, Thorsten; Rueffer, U.; Koch, Tina; Naumann, R. Wendel; Boissevain, F.; Koch, P.; Worst, P.; Soekler, Martin; Eich, Hans Theodor; Müller-Hermelink, H. K.; Franklin, Jeremy; Paulus, U.; Wolf, Jürgen; Engert, Andreas; Diehl, Volker

doi:10.1200/jco.2003.06.028

Cited by 79 publications

(44 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although ABVD was intensively used after the 1990s, the most common treatment regimen was COPP in previous years. The standard treatment regimen is ABVD in early-stage patients and bleomycin, etoposide, doxorubicin, Overall Survival cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP) or dose-escalated BEACOPP for advancedstage disease (15)(16)(17)(18)(19)(20). HL has become a more curable disease recently due to the novel diagnostic methods and potent treatment regimens.…”

Section: Discussionmentioning

confidence: 99%

Clinical Features and Prognostic Factors of Hodgkin’s Lymphoma: A Single Center Experience

Kilickap¹,

Barışta²,

Ülger³

et al. 2013

Balkan Med J

View full text Add to dashboard Cite

Background: Hodgkin's lymphoma (HL) is a B cell lymphoma characterized by the presence of Reed-Sternberg cells. HL comprises 1% of all cancer cases and 14% of all lymphoma cases. Aims:We designed a retrospective study to investigate the clinical features and prognostic factors of HL patients diagnosed at an experienced oncology centre.Study Design: Retrospective study.Methods: Demographic characteristics, histopathological and clinical features, treatment modalities and response to treatment were obtained from hospital records. Dates of initial diagnosis, remission and relapse, last visit and death were recorded for survival analyses.Results: We analysed data of 391 HL patients (61% male, 39% female; mean age 35.7±15.1 years). The most common classical HL histological subtype was nodular sclerosing HL (NSHL) (42.7%). The most common stage was II 50.4%. The most common chemotherapy regimen was doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) (70.6%). Five and 10-year survival rates were 90% and 84%, respectively. Early-stage patients with good prognostic factors had better overall and relapse-free survival rates. The presence of "B" symptoms, albumin level, Eastern Cooperative Oncology Group (ECOG) performance score, and LDH were prognostic factors that affect the survival in both univariate and multivariate analyses.Conclusion: This is the first study that demonstrates the demographic, clinical and prognostic features of HL patients in Turkey, and provides a general picture of the HL patients in our country.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Features and Prognostic Factors of Hodgkin’s Lymphoma: A Single Center Experience

Kilickap¹,

Barışta²,

Ülger³

et al. 2013

Balkan Med J

View full text Add to dashboard Cite

show abstract

“…All trials were conducted in accordance with the Declaration of Helsinki and are described in detail elsewhere. [8][9][10][11][12][13][14][15][16][17][18] This is a retrospective analysis including data of patients initially treated within prospective clinical studies. These studies were approved by institutional review boards before beginning study enrolment.…”

Section: Patients and Hl Treatmentmentioning

confidence: 99%

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

Eichenauer

Thielen

Haverkamp

et al. 2014

Blood

122

View full text Add to dashboard Cite

Key Points• Occurrence of t-AML/MDS after Hodgkin lymphoma is a rare event correlating with the intensity of first-line chemotherapy.• Allogeneic stem cell transplantation appears to improve the generally poor prognosis of patients with t-AML/MDS after Hodgkin lymphoma.Therapy-related acute myeloid leukemia and myelodysplastic syndromes (t-AML/MDS) represent severe late effects in patients treated for Hodgkin lymphoma (HL). Because more recent data are scarce, we retrospectively analyzed incidence, outcome, and risk factors for the development of t-AML/MDS after HL. A total of 11 952 patients treated for newly diagnosed HL within German Hodgkin Study Group trials between 1993 and 2009 were considered. At a median follow-up of 72 months, t-AML/MDS was diagnosed in 106/11 952 patients (0.9%). Median time from HL treatment to t-AML/MDS was 31 months. The median age of patients with t-AML/MDS was higher than in the whole patient group (43 vs 34 years, P < .0001). Patients who received 4 or more cycles of BEACOPP escalated had an increased risk to develop t-AML/MDS when compared with patients treated with less than 4 cycles of BEACOPP escalated or no BEACOPP chemotherapy (1.7% vs 0.7% vs 0.3%, P < .0001). The median overall survival (OS) for all t-AML/MDS patients was 7.2 months. However, t-AML/ MDS patients proceeding to allogeneic stem cell transplantation had a significantly better outcome with a median OS not reached after a median follow-up of 41 months (P < .001).

show abstract

“…5,12 Central PET review panel A multidisciplinary panel consisting of a medical oncologist, a radiologist, a radiation oncologist, and a nuclear medicine physician, accompanied by a statistician, reviewed PET and CT scans as well as available conventional X-rays blinded to the treatment arm. Inclusion and exclusion criteria were also assessed.…”

Section: Chemotherapymentioning

confidence: 99%

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Kobe

Dietlein

Franklin

et al. 2008

Blood

200

View full text Add to dashboard Cite

In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV) of positron emission tomography (PET) using [ 18 F]-fluorodeoxyglucose in advanced-stage Hodgkin lymphoma (HL) was evaluated. A total of 817 patients were enrolled and randomly assigned to receive BEACOPP-based chemotherapy. After completion of chemotherapy, residual disease measuring more than or equal to 2.5 cm in diameter was assessed by PET in 311 patients. The NPV of PET was defined as the proportion of PET ؊ patients without progression, relapse, or irradiation within 12 months after PET review panel. The progression-free survival was 96% for PET ؊ patients (95% confidence interval [CI], 94%-99%) and 86% for PET ؉ patients (95% CI, 78%-95%, P ‫؍‬ .011). The NPV for PET in this analysis was 94% (95% CI, 91%-97%). Thus, consolidation radiotherapy can be omitted in PET ؊ patients with residual disease without increasing the risk for progression or early relapse compared with patients in complete remission. The impact of this finding on the overall survival at 5 years must be awaited. Until then, response adapted therapy guided by PET for HL patients seems to be a promising approach that should be further evaluated in clinical trials. This trial is registered at http://isrctn.org study as #IS-RCTN32443041.(Blood. 2008;112: 3989-3994)

show abstract

14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of a Pilot Study of the German Hodgkin’s Lymphoma Study Group

Cited by 79 publications

References 18 publications

Clinical Features and Prognostic Factors of Hodgkin’s Lymphoma: A Single Center Experience

Clinical Features and Prognostic Factors of Hodgkin’s Lymphoma: A Single Center Experience

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Contact Info

Product

Resources

About